Approval

European Commission Approves AbbVie Skyrizi To Treat Moderate To Severe Active Crohns Disease

November 24,2022 04:50 AM
- By Admin

AbbVie announced the European Commission (EC) approved Skyrizi (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

"There are still many patients suffering from debilitating symptoms associated with Crohn's disease, such as abdominal pain and stool frequency, which is why we've embraced the challenge of serving these patients in need," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "The approval of Skyrizi in the European Union is a significant milestone in our pursuit to expand our IBD portfolio."

The EC approval for Skyrizi in Crohn's disease is supported by results from the global phase 3 programme, which included three studies: ADVANCE induction, MOTIVATE induction and FORTIFY maintenance. The three phase 3 studies are multicenter, randomized, double-blind, placebo-controlled studies and include assessments of efficacy, safety and tolerability of Skyrizi.

In the ADVANCE and MOTIVATE induction trials, a significantly greater proportion of patients treated with Skyrizi 600 mg IV achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response.

In ADVANCE and MOTIVATE, 43% and 35% of patients treated with Skyrizi 600 mg IV achieved clinical remission at week 12, respectively, compared to 22% and 19% of patients receiving placebo.

Additionally, 40% and 29% of Skyrizi treated patients achieved endoscopic response at week 12 compared to 12% and 11% of patients receiving placebo.

In the FORTIFY maintenance trial, a significantly greater proportion of patients treated with Skyrizi 360 mg SC achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response.

In FORTIFY, 52% of patients treated with Skyrizi 360 mg SC achieved clinical remission at week 52 compared to 40% of patients receiving placebo.

Additionally, 47% of patients treated with Skyrizi achieved endoscopic response at week 52 compared to 22% of patients receiving placebo.

During the ADVANCE and MOTIVATE induction studies, a significantly greater proportion of patients treated with Skyrizi 600 mg IV achieved mucosal healing and endoscopic remission.

In ADVANCE and MOTIVATE, 21% and 14% of patients treated with Skyrizi 600 mg IV achieved mucosal healing at week 12, respectively, compared to 8% and 4% of patients receiving placebo.

Additionally, during the induction studies, 24% and 19% of patients treated with Skyrizi 600 mg IV achieved endoscopic remission at week 12, respectively, compared to 9% and 4% of patients receiving placebo.

Mucosal healing and endoscopic remission were observed during the FORTIFY maintenance trial in patients treated with Skyrizi 360 mg SC.

In FORTIFY, mucosal healing was observed at week 52 in 31% of patients treated with Skyrizi 360 mg SC compared to 10% of patients receiving placebo (nominal p-value<0.001).

Additionally, endoscopic remission was observed at week 52 in 39% of patients treated with Skyrizi 360 mg SC compared to 13% of patients receiving placebo (nominal p-value<0.001).

"Beyond managing daily symptoms, clinical remission and endoscopic goals are key treatment targets in Crohn's disease," said Marc Ferrante, M.D., Ph.D., Department of Gastroenterology and Hepatology, University Hospitals Leuven, Belgium. "Research advancements have made it possible for patients to aim for higher treatment goals, including mucosal healing. The approval of Skyrizi as the first IL-23 inhibitor for moderate to severe Crohn's disease is a critical step forward towards a treatment option that can support a patient's health goals."

Additionally, across all three studies, safety results of Skyrizi in Crohn's disease were consistent with the known safety profile of Skyrizi, with no new safety risks observed. In ADVANCE, the most common adverse events (AEs) observed in the Skyrizi treatment groups were headache, nasopharyngitis and fatigue. In MOTIVATE, the most common AEs observed were headache, arthralgia and nasopharyngitis. In FORTIFY, the most common AEs were exacerbation of Crohn's disease, nasopharyngitis and arthralgia.

Skyrizi is also approved in the EU for the treatment of adults with psoriasis and psoriatic arthritis.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhoea and abdominal pain. It is a progressive disease, meaning it gets worse over time in a substantial proportion of patients or may develop complications that require urgent medical care, including surgery. Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically, but also emotionally and economically.

The three phase 3 studies are multicenter, randomized, double-blind, placebo-controlled studies to evaluate the efficacy and safety of Skyrizi 600 mg and 1200 mg as induction therapy, and Skyrizi 180 mg and 360 mg as maintenance therapy in subjects with moderately to severely active Crohn's disease.

Skyrizi is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit.7 IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases. Phase 3 trials of Skyrizi in psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis are ongoing.

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.


AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.